S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:AKBA

Akebia Therapeutics (AKBA) Stock Price, News & Analysis

$1.83
-0.41 (-18.30%)
(As of 03/28/2024 ET)
Today's Range
$1.77
$2.47
50-Day Range
$1.35
$2.24
52-Week Range
$0.49
$2.48
Volume
60.94 million shs
Average Volume
4.19 million shs
Market Capitalization
$383.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Akebia Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
173.2% Upside
$5.00 Price Target
Short Interest
Healthy
4.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
0.43mentions of Akebia Therapeutics in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$300,598 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.27) to ($0.19) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.16 out of 5 stars

Medical Sector

180th out of 938 stocks

Pharmaceutical Preparations Industry

70th out of 426 stocks

AKBA stock logo

About Akebia Therapeutics Stock (NASDAQ:AKBA)

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AKBA Stock Price History

AKBA Stock News Headlines

[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
U.S. FDA approves Akebia's anemia drug
Akebia Awaits FDA Word On Second Crack At Vadadustat
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
Recap: Akebia Therapeutics Q4 Earnings
Akebia Therapeutics earnings: here's what Wall Street expects
Earnings Preview For Akebia Therapeutics
See More Headlines
Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKBA
Employees
204
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+177.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-51,920,000.00
Pretax Margin
-26.68%

Debt

Sales & Book Value

Annual Sales
$194.62 million
Book Value
($0.16) per share

Miscellaneous

Free Float
201,332,000
Market Cap
$376.87 million
Optionable
Optionable
Beta
0.78
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives


AKBA Stock Analysis - Frequently Asked Questions

Should I buy or sell Akebia Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKBA shares.
View AKBA analyst ratings
or view top-rated stocks.

What is Akebia Therapeutics' stock price target for 2024?

3 analysts have issued 1 year price targets for Akebia Therapeutics' stock. Their AKBA share price targets range from $4.00 to $6.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 173.2% from the stock's current price.
View analysts price targets for AKBA
or view top-rated stocks among Wall Street analysts.

How have AKBA shares performed in 2024?

Akebia Therapeutics' stock was trading at $1.24 at the beginning of 2024. Since then, AKBA stock has increased by 47.6% and is now trading at $1.83.
View the best growth stocks for 2024 here
.

Are investors shorting Akebia Therapeutics?

Akebia Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 10,130,000 shares, an increase of 24.9% from the February 29th total of 8,110,000 shares. Based on an average daily trading volume, of 3,010,000 shares, the short-interest ratio is currently 3.4 days.
View Akebia Therapeutics' Short Interest
.

When is Akebia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our AKBA earnings forecast
.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) issued its earnings results on Thursday, March, 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts' consensus estimates of ($0.04). The biopharmaceutical company had revenue of $56.20 million for the quarter, compared to analysts' expectations of $55.64 million. During the same quarter in the prior year, the business earned ($0.04) EPS.

What ETF holds Akebia Therapeutics' stock?

Invesco Nasdaq Future Gen 200 ETF holds 33,325 shares of AKBA stock, representing 0.72% of its portfolio.

What is John Butler's approval rating as Akebia Therapeutics' CEO?

28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.83%), Vanguard Group Inc. (3.83%), Federated Hermes Inc. (0.46%), Northern Trust Corp (0.16%), Sapient Capital LLC (0.11%) and Sapient Capital LLC (0.10%). Insiders that own company stock include David A Spellman, John P Butler, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau.
View institutional ownership trends
.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKBA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners